Outcome of Treatment of Human HeLa Cervical Cancer Cells With Roscovitine Strongly Depends on the Dosage and Cell Cycle Status Prior to the Treatment

0337483 - ÚEB 2010 RIV US eng J - Článek v odborném periodiku
Wesierska-Gadek, J. - Borza, A. - Walzi, E. - Kryštof, Vladimír - Maurer, M. - Komina, O. - Wandl, S.
Outcome of Treatment of Human HeLa Cervical Cancer Cells With Roscovitine Strongly Depends on the Dosage and Cell Cycle Status Prior to the Treatment.
Journal of Cellular Biochemistry. Roč. 106, č. 5 (2009), s. 937-955. ISSN 0730-2312. E-ISSN 1097-4644
Výzkumný záměr: CEZ:AV0Z50380511
Klíčová slova: APOPTOSIS * CELL CYCLE ARREST * CYCLIN-DEPENDENT KINASES
Kód oboru RIV: ED - Fyziologie
Impakt faktor: 2.935, rok: 2009

Exposure of asynchronously growing human HeLa cervical carcinoma cells to roscovitine (ROSC), a selective cyclin-dependent kinases (CDKs) inhibitor, arrests their progression at the transition between G(2)/M and/or induces apoptosis. The outcome depends on the ROSC concentration. At higher close ROSC represses HPV-encoded E7 oncoprotein and initiates caspase-dependent apoptosis. Inhibition of the site-specific phosphorylation of survivin and Bad, occurring at high-dose ROSC treatment, precedes the onset of apoptosis and seems to be a prerequisite for cell death. Considering the fact that in HeLa cells the G(1)/S restriction checkpoint is abolished by E7, we addressed the question whether the inhibition of CDKs by pharmacological inhibitors in synchronized cells would be able to block the cell-cycle in G, phase. For this purpose, we attempted to synchronize cells by serum withdrawal or by blocking of the mitotic apparatus using nocodazole.
Trvalý link: http://hdl.handle.net/11104/0181463